[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100624963":3},{"organization":4,"outcomesModule":7,"designInfo":31,"detailedDescription":34,"studyPopulation":35,"armGroups":36,"interventions":45,"overallOfficials":51,"centralContacts":56,"locations":66,"responsibleParty":84,"collaborators":30,"id":86,"slug":87,"hasResults":88,"nctId":89,"briefTitle":90,"officialTitle":91,"acronym":92,"eligibilityCriteria":93,"healthyVolunteers":88,"sex":94,"minAge":30,"maxAge":30,"enrollmentInfo":95,"targetDuration":30,"studyType":98,"phases":30,"briefSummary":99,"conditions":100,"keywords":104,"overallStatus":69,"whyStopped":30,"lastUpdateSubmitDate":112,"lastUpdatePostDateStruct":113,"startDateStruct":116,"completionDateStruct":118,"leadSponsor":120,"locationsCount":121},{"fullName":5,"class":6},"International Vaccine Institute","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":30},[9],{"measure":10,"description":11,"timeFrame":12},"Blood culture-confirmed iNTS disease (including malaria co-infections) in participants who received complete malaria vaccination vs. unvaccinated participants.","Among individuals seeking care for symptoms consistent with clinical malaria\u002FiNTS, those who have received the full recommended regimen of the R21\u002FMatrix-M malaria vaccine will have a 1.00 - 0.38 or lower odds of blood-culture confirmed iNTS.","At presentation (enrollment)",[14,17,20,23,26],{"measure":15,"description":16,"timeFrame":12},"Blood culture-confirmed iNTS disease (including malaria co-infections) in participants who received any dose of malaria vaccine vs. unvaccinated participants.","Among individuals seeking care for symptoms consistent with clinical malaria\u002FiNTS, those who have received any dose of the R21\u002FMatrix-M malaria vaccine will have a 1.00 - 0.19 or lower odds of blood-culture confirmed iNTS.",{"measure":18,"description":19,"timeFrame":12},"Culture-confirmed iNTS disease (including malaria co-infections) in participants with at least one severity feature and who received complete malaria vaccination vs. unvaccinated participants.","Among individuals seeking care for symptoms consistent with clinical malaria\u002FiNTS and meeting the definition for severe disease at first presentation to the enrolling healthcare facility, those who have received the full recommended regimen of the R21\u002FMatrix-M malaria vaccine will have a 1.00 - 0.57 or lower odds of blood-culture confirmed iNTS.",{"measure":21,"description":22,"timeFrame":12},"Blood culture-confirmed iNTS disease (including malaria co-infections) in participants with at least one severity feature and who received any dose of the malaria vaccine vs. unvaccinated participants.","Among individuals seeking care for symptoms consistent with clinical malaria\u002FiNTS and meeting the definition for severe disease at first presentation to the enrolling healthcare facility, those who have received any dose of the R21\u002FMatrix-M malaria vaccine will have a 1.00 - 0.38 or lower odds of blood-culture confirmed iNTS.",{"measure":24,"description":25,"timeFrame":12},"mRDT, blood smear and\u002For PCR-confirmed malaria disease, including severe malaria cases, with or without culture-confirmed iNTS disease, in participants who received complete malaria vaccination vs. unvaccinated participants","Among individuals seeking care for symptoms consistent with clinical malaria\u002FiNTS, those who have received the full recommended regimen of the R21\u002FMatrix-M malaria vaccine will have a 1.00 - 0.75 or lower odds of test-positive malaria infection.",{"measure":27,"description":28,"timeFrame":29},"Impact of vaccination using R21\u002FMatrix-M on the incidence of culture-confirmed iNTS and mRDT, blood smear and\u002For PCR confirmed malaria co-infection (before\u002Fafter)","Among individuals seeking care for symptoms consistent with clinical malaria\u002FiNTS (age-cohorts exposed to R21\u002FMatrix-M vaccination program), relative rate of healthcare-ascertained, laboratory-confirmed malaria-iNTS co-infections 1-year-after versus before the introduction of the program will be 1.00 - 0.38 or lower.","2 years",null,{"allocation":30,"interventionModel":30,"interventionModelDescription":30,"primaryPurpose":30,"observationalModel":32,"timePerspective":33,"maskingInfo":30},"CASE_CONTROL","PROSPECTIVE","* This study builds on existing febrile illnesses surveillance in the Kisantu Health Zone, which enrolls patients presenting to participating healthcare facilities with fever.(See specific eligibility criteria)\n* For participants eligible to receive the malaria vaccine (6-24 months) and included in the study at the surveillance sites (presenting with fever), malaria vaccination status is ascertained with the Expanded Program of Immunization (EPI) card, Alternatively, a dedicated vaccination registration database that was set-up in the study catchment area is searched. The study team can also visit participants' house to verify the EPI vaccination card. R21\u002FMatrix-M malaria vaccine was rolled out in the Kisantu Health Zone as part of the Expanded Program on Immunizations (DRC Ministry of Public Health) on 29th of October 2024.\n* The laboratory diagnosis of iNTS uses automated blood culture method. Malaria diagnosis is confirmed with microscopic examination of blood smears. Malaria Rapid Diagnostic Tests (mRDTs) are also performed for all participants for routine clinical management and rapid treatment guidance at the healthcare facility level. For laboratory-confirmed iNTS cases, malaria parasitemia and species specification is confirmed by Polymerase Chain Reaction (PCR).\n* All participants with positive blood culture to iNTS and\u002For a confirmed malaria parasitemia receive antibacterial and\u002For antimalarial treatment in accordance with national guidelines. Hospitalized cases with confirmed iNTS, with or without malaria co-infection, are followed until hospital discharge or death. Participants with a positive blood culture for iNTS and discharged after enrollment are followed every 7 to 9 days until disease resolution (defined as no fever in the past 24 hours), death, or up to 21 days post-enrollment to assess symptom severity, hospitalization, and disease outcome.","Though only children 6-24 months of age are eligible to receive R21\u002FMatrix-M, patients of all age groups presenting with fever at participating sites will be monitored for malaria and iNTS.",[37,42],{"label":38,"type":30,"description":39,"interventionNames":40},"Age-eligible children who received the R21\u002FMatrix-M Malaria Vaccine.","Depending on the study objective, participants who received at least the three primary doses of the R21\u002FMatrix-M vaccine will be considered for analysis (complete vaccination - primary objective) or participants who received either the first or first two doses of R21\u002FMatrix-M vaccine (incomplete vaccination - secondary objectives) shall be considered for analysis.",[41],"Biological: R21\u002FMatrix-M malaria vaccine",{"label":43,"type":30,"description":44,"interventionNames":30},"Age-eligible children who were not vaccinated against malaria.","Unvaccinated participants will be defined as not meeting the definitions for complete nor incomplete vaccination by time of enrollment.",[46],{"type":47,"name":48,"description":49,"armGroupLabels":50,"otherNames":30},"BIOLOGICAL","R21\u002FMatrix-M malaria vaccine","R21\u002FMatrix-M malaria vaccination was introduced by DRC Ministry of Public Health in the Expanded Program on Immunizations on 29th of October 2024. Children aged 6 months to 24 months are eligible to receive the vaccine. Vaccination follows a 4 doses schedule: a first dose administered between 6 and 11 months of age, a second dose one month after the first dose, a third dose one month after the second dose and a booster dose seven months after the third dose.",[38],[52],{"name":53,"affiliation":54,"role":55},"Octavie Lunguya","Institut National de Recherche Biomedicale","PRINCIPAL_INVESTIGATOR",[57,62],{"name":58,"role":59,"phone":60,"phoneExt":30,"email":61},"Birkneh Tadesse, MD, PHD","CONTACT","+821098041348","Birkneh.Tadesse@ivi.int",{"name":63,"role":59,"phone":64,"phoneExt":30,"email":65},"Camille Dauvergne, PharmD, M.S.c","+821091480309","Camille.Dauvergne@ivi.int",[67],{"facility":68,"status":69,"city":70,"state":30,"zip":30,"country":71,"countryCode":72,"cosmosGeoPoint":73,"geoPoint":78,"contacts":79},"Institut National de Recherche Biomedicale (INRB)","RECRUITING","Kinshasa","Democratic Republic of the Congo","CD",{"type":74,"coordinates":75},"Point",[76,77],15.31357,-4.32758,{"lat":77,"lon":76},[80],{"name":81,"role":59,"phone":82,"phoneExt":30,"email":83},"Octavie Lunguya, PHD","+243815181121","octmetila@yahoo.fr",{"type":85,"investigatorFullName":30,"investigatorTitle":30,"investigatorAffiliation":30,"oldNameTitle":30,"oldOrganization":30},"SPONSOR","100624963","effectiveness-of-malaria-vaccines-in-reducing-the-risk-of-invasive-non-typhoidal-salmonella-disease-100624963",false,"NCT07416461","Effectiveness of Malaria Vaccines in Reducing the Risk of Invasive Non-typhoidal Salmonella Disease","Effectiveness of Malaria Vaccines in Reducing the Risk of Invasive Non-Typhoidal Salmonella Disease (VINS)","VINS","Inclusion Criteria:\n\n1. Patients of all ages currently living in the catchment area of the health center presenting to healthcare facility with objective fever of at least 38.0°C tympanic or 37.5 °C axillary OR\n2. Patients of all ages currently living in the catchment area of the health center presenting to healthcare facility with reported fever ≥3 consecutive days within 7 days of presentation","ALL",{"count":96,"type":97},10000,"ESTIMATED","OBSERVATIONAL","The goal of this observational study is to learn about the impact of malaria vaccination on the risk of invasive non-typhoidal Salmonella disease in children below the age of 5. Eligible participants residing in the Kisantu Health Zone (DRC) and presenting fever are enrolled in healthcare facilities and tested for malaria and iNTS. Using a case-control (test-negative) design, the researchers will look at the malaria vaccination status of participants with and without iNTS infection to determine if the malaria vaccine protects against iNTS.",[101,102,103],"Invasive Non-Typhoidal Salmonella Disease","Malaria","Malaria Vaccine",[102,105,106,101,107,108,109,110,111],"Vaccine effectiveness","iNTS","DRC","Democratic Republic of Congo","Malaria vaccine","Effectiveness","R21\u002FMatrix-M","2026-02-10",{"date":114,"type":115},"2026-02-18","ACTUAL",{"date":117,"type":115},"2025-10-27",{"date":119,"type":97},"2027-02",{"name":5,"class":6},1]